Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...

Gilead Sciences continues to focus on advancing medicines to combat diseases like HIV, viral hepatitis, COVID-19, and cancer, operating in over 35 countries with its headquarters in Foster City ...

Cognizant  has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences  that aims to unlock even greater value for Gilead as it advances innovations to ...

Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

(Reuters) - Gilead Sciences and the U.S. government have settled ... for comment and more information about the settlement. Foster City, California-based Gilead collaborated with the CDC in ...

(Reuters) - Gilead Sciences (NASDAQ:GILD ... to a request for comment and more information about the settlement. Foster City, California-based Gilead collaborated with the CDC in the mid-2000s ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion ... respond to a request for comment and more information about the settlement. Foster City, California-based Gilead ...

Gilead Sciences, US Government Settle Patent Case ... to a request for comment and more information about the settlement. Foster City, California-based Gilead collaborated with the CDC in the ...